Tadalafil: Beyond Erectile Dysfunction to Potential Health Benefits
Tadalafil, widely known by its brand name Cialis, is a common prescription for erectile dysfunction. Recently, some wellness enthusiasts and biohackers have touted this medication for purposes beyond its original use. Online clinics and key personalities promote tadalafil as a potential longevity drug, claiming benefits for cardiovascular health, brain function, and athletic performance. Despite these claims, the drug lacks approval for heart attack or stroke prevention, let alone life extension.
Dr. Robert Kloner, chief science officer at the Huntington Medical Research Institute and professor at the University of Southern California, highlights serious discussions about this topic. Cardiovascular disease remains the leading cause of death, and there is growing interest in tadalafil’s potential preventive health benefits.
The Longevity Buzz
Tadalafil belongs to the same class of drugs as sildenafil, or Viagra, but its effects last longer. Although both drugs have long been available, recent studies indicate that users of tadalafil may benefit from lower rates of cardiovascular disease, dementia, and death. These studies primarily show associations and cannot definitively conclude that tadalafil is the cause.
Dr. Kloner notes that results from various studies, including those conducted in his lab, have been consistent. This has sparked interest in the longevity community. Figures like Stanford neuroscientist Andrew Huberman and tech mogul Bryan Johnson support using tadalafil for more than sexual health.
Kristi Sawicki, who holds a doctorate in molecular oncology, describes tadalafil as seemingly harmless. She began taking it a year ago and reports benefits like improved blood flow, potentially advantageous for the brain and heart. This aligns with her family history of heart disease, viewing tadalafil as simple cardiovascular protection.
Research and Findings
Beyond erectile dysfunction, tadalafil and sildenafil treat a rare type of pulmonary hypertension and symptoms of an enlarged prostate. These drugs, known as PDE-5 inhibitors, optimize blood flow by relaxing smooth muscles and dilating vessels throughout the body.
Sildenafil was originally developed for treating chest pain caused by compromised heart blood flow until its “side effects” indicated other potential uses. Small trials suggest PDE-5 inhibitors might benefit blood vessels and exhibit anti-inflammatory effects.
Studies from medical records indicate significant impacts for men prescribed these drugs. For instance, an analysis involving over 8,000 men on tadalafil showed a 55% reduction in cardiovascular mortality and a 44% decrease in overall mortality. Another study involving half a million patients suggested a 32% lower risk of dementia among tadalafil users.
Dr. Dietrich Jehle, chair of emergency medicine at UTMB, highlights particular interest in the connection with dementia, bolstered by data suggesting decreased Alzheimer’s risk. Researchers stress caution without prospective and randomized studies.
The challenge, as noted by Kloner, is the absence of incentives for pharmaceutical companies to conduct costly research on generic drugs. He emphasizes that while these drugs appear safe, cardiologists do not routinely recommend them for this broader use.
Online Market and Expert Opinions
Many online clinics market tadalafil alongside other wellness therapies, often without solid human data backing. Companies like AgelessRx offer low-dose tadalafil for longevity, charging $70 a month.
Dr. Jenell Decker, medical director of AgelessRx, acknowledges the necessity to infer benefits for longevity, citing a lack of trials for people before they show symptoms. Yet, experts like Dr. Steve Nissen from the Cleveland Clinic caution against the off-label use without robust trial data.
Acceptance Among Medical Expert Panels
Tadalafil’s expanded use has gained traction beyond online circles, as shown by discussions in a recent meeting of the Princeton Consensus Panel, focusing on men’s sexual and cardiovascular health. Consisting of experts like Kloner, the group agreed on advocating low-dose tadalafil for men at higher cardiovascular risk, although their recommendations are unpublished.
Dr. Martin Miner, co-chair of the panel’s conference, acknowledges hesitance due to the lack of randomized trials. Nonetheless, the panel supports this use based on existing observational data, noting it’s not suitable for all men.
Miner directs the Men’s Health Center at Brown University and prescribes tadalafil to patients at higher cardiovascular risk, emphasizing the need to bridge the longevity gap for men in the U.S.